Novabay Pharmaceuticals (NYSEAMERICAN: NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN: NBY)

Official NovaBay Pharmaceuticals Logo

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN: NBY) is a commercial stage biopharmaceutical company headquartered in Emergyville, California. Founded in the year 2000, the company has three products currently on the market. These include:

Avenova – A product designed for daily eyelash and eyelid hygiene, cleaning bacteria that are known to contribute to 85% of the dry eye market.
NeutroPhase – A product designed for skin and wound care.
CelleRx – A clensing solution that cleans, calms and soothes after cosmetic procedures.

Visit the NovaBay Pharmaceuticals investor relations website here.

Recent Novabay Pharmaceuticals (NYSEAMERICAN: NBY) Reports From Alpha Stock News

NovaBay Pharmaceuticals (NBY) Stock Rockets On Regulatory News

Joshua Rodriguez - September 24, 2019

NovaBay Pharmaceuticals (NBY) Stock Rockets On Sales

July 29, 2019

NovaBay Pharmaceuticals (NBY) Stock Falls But Not For Long

June 12, 2019

Recent NovaBay Pharmaceuticals (NYSEAMERICAN: NBY) Press Releases

Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests September 24, 2019
British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]
NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in Australia September 24, 2019
“We are pleased to receive approval to market Avenova in Australia and are planning to engage a distributor in the near term,” said Justin Hall, NovaBay president and CEO. “This marks another step forward in our goal to increase the availability of Avenova to dry eye sufferers. Avenova is the only commercially available pure hypochlorous […]
NovaBay Pharmaceuticals Names Finance Executive Jeff Zheng to its Board of Directors September 16, 2019
Dr. Zheng will chair the nominating and corporate governance committee, and will serve on the audit and compensation committees. “Jeff brings us extensive corporate governance and financial experience that includes a track record of providing innovative corporate financing solutions from his many years in an advisory capacity to microcap companies.
NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock August 9, 2019
The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock convertible from the preferred stock, the accompanying warrants and the common stock issuable upon exercise of the warrants will not be registered […]
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering August 9, 2019
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a […]